Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression

NCT05328297 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT05328297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05328297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 2
Overall status
Completed
Start date
June 3, 2022
Completion date
May 17, 2024
Enrollment
116 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder